What is the future of CAR-T research and therapeutics?
CAR-T cells have already demonstrated notable results when used to treat B-cell cancers, but much work remains to optimize these engineered cytotoxic agents against other cancers, especially solid tumors.1,3 However, the possibilities for CAR development and engineering are almost limitless, and researchers have many options available to them as they continue to pursue improvements in antigen selection, targeting specificity, side effect amelioration, and better control of the duration and magnitude of the immune response.1,2 Progress is also being made regarding CAR-T cell production throughput, efficiency, and cost. This work will help ensure that CAR-T research and manufacture is stringent, standardized, and accessible to as many scientists (and patients) as possible around the world.4
References:
1. S. Yu, et al., “Chimeric antigen receptor T cells: a novel therapy for solid tumors,” J Hematol Oncol 10(1):78, 2017
2. G. Dotti, et al., “Design and Development of Therapies using Chimeric Antigen Receptor-Expressing T cells,” Immunol Rev 257(1):10, 2014.
3. J. Hartmann, et al., “Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts,” EMBO Mol Med 9(9):1183-1197, 2017.
4. B.L. Levine, et al., “Global Manufacturing of CAR T Cell Therapy,” Mol Ther Methods Clin Dev, 4:92-101, 2016.
References:
1. S. Yu, et al., “Chimeric antigen receptor T cells: a novel therapy for solid tumors,” J Hematol Oncol 10(1):78, 2017
2. G. Dotti, et al., “Design and Development of Therapies using Chimeric Antigen Receptor-Expressing T cells,” Immunol Rev 257(1):10, 2014.
3. J. Hartmann, et al., “Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts,” EMBO Mol Med 9(9):1183-1197, 2017.
4. B.L. Levine, et al., “Global Manufacturing of CAR T Cell Therapy,” Mol Ther Methods Clin Dev, 4:92-101, 2016.
